Institutional consensus predicts that innovative drug concept stocks are expected to continue growing in performance over the next two years

Zhitong
2025.06.09 04:56

According to statistics, innovative drug concept stocks have shown strong performance this year, with an average increase of 27.34%, significantly outperforming the market. Six individual stocks have doubled in price this year. Among them, Staidson BioPharm has the highest price increase, with a cumulative rise of 292.98% this year; Sangfor Technologies, Sinovac Biotech, LIANHE TECHNOLOGY, and others have all seen price increases exceeding 100% this year. Currently, among the innovative drug concept stocks rated by five or more institutions, 19 stocks are expected to maintain a net profit growth of over 20% in 2025-2026. Betta Pharmaceuticals, AMOYTOP, Haoyuan Pharmaceutical, and Ganli Pharmaceuticals have received increased leverage funding this month

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer